These press releases are for business and financial media.
-
- 05 May 2004
- SUCCESSFUL OUTCOME OF THE MUTUAL RECOGNITION PROCEDURE FOR EXANTA™ (XIMELAGATRAN) IN EUROPE AstraZeneca announced today that it has successfully completed the Mutual Recognition Procedure (MRP) in Europe for Exanta™ (ximelagatran) for short-term use in the prevention of venous thromboembolic events in major elective orthopaedic surgery (hip or knee replacement) – the ‘proof of concept’ indication for this new anticoagulant.
-
- 04 May 2004
- ASTRAZENECA ANNOUNCES MAJOR INVESTMENT TO SUPPORT WORLDWIDE GROWTH OF SYMBICORT AstraZeneca today announced a major investment in new production facilities to support the further growth of Symbicort, the Company’s key respiratory product for the treatment of asthma and chronic obstructive pulmonary disease (COPD). Representing an investment of over $114 million, this latest development will result in the creation of around 150 new manufacturing jobs at AstraZeneca’s production site in Dunkerque, France.
-
- 29 April 2004
- AstraZeneca PLC First Quarter Results 2004 “First quarter sales exceed $5 billion. Financial targets for the year on track.”
-
- 19 April 2004
- NEW STUDIES CONFIRM SUPERIORITY OF CRESTOR™ COMPARED TO ATORVASTATIN IN PATIENTS WITH TYPE 2 DIABETES AND DYSLIPIDAEMIA New data released at the European Atherosclerosis Society (EAS) Congress in Seville show that CRESTOR™(rosuvastatin) significantly reduces LDL-cholesterol (LDL-C or ‘bad’ cholesterol) in patients with type 2 diabetes and dyslipidaemia (high cholesterol) more than atorvastatin.
-
- 07 April 2004
- ASTRAZENECA SUBMITS REGULATORY APPLICATION IN EUROPE FOR THE USE OF ATACAND® IN THE TREATMENT OF HEART FAILURE AstraZeneca today announced the submission of a regulatory application in the European Union (EU), as part of the Mutual Recognition Variation Procedure to obtain a new indication for Atacand (candesartan cilexetil), its angiotensin II type 1 (AT1) receptor blocker, for use in the treatment of heart failure (CHF). The UK acts as the RMS (Reference Member State). Further filings in the US and other markets are expected in the near future.
-
- 31 March 2004
- ASTRAZENECA CEO CALLS FOR INTEGRATED BIOMEDICAL RESEARCH STRATEGY AT AMS LECTURE Sir Tom McKillop, Chief Executive AstraZeneca PLC, today will call for an integrated biomedical research strategy and a European Market Place ready to reward innovation to reverse Europe’s relative decline in biomedical research. Sir Tom McKillop will make these remarks when he delivers the Second Annual Forum Lecture to the Academy of Medical Sciences (AMS).
-
- 22 March 2004
- SYMBICORT® SINGLE INHALER THERAPY (SYMBICORT® SiT) DEMONSTRATES SUPERIOR ASTHMA CONTROL USING ONLY ONE INHALER New data, announced today at the American Academy of Allergy, Asthma and Immunology (AAAAI), San Francisco, highlights the benefits of Symbicort®(budesonide/formoterol) Single inhaler Therapy (Symbicort® SiT), a new approach to asthma management. The research shows that superior asthma control is achieved by using just one inhaler combining both maintenance and reliever medication, compared to traditional asthma treatment with a higher fixed daily dose of an inhaled corticosteroid and a separate rescue
-
- 16 March 2004
- ASTRAZENECA ANNOUNCES LATEST PHASE OF UK £1 BILLION INVESTMENT PROGRAMME AstraZeneca has announced two major investments in the UK with the imminent opening of major new facilities in Alderley Park, Macclesfield, Cheshire, and additional investment to support the development of its research site in Charnwood, Loughborough, Leicestershire. These latest developments will mean that AstraZeneca’s investment in the UK (from 1999 and planned until 2006), will have approached a potential £1 billion, with the creation of well over 550 new science related jobs.
-
- 12 March 2004
- MARKETING APPROVAL GRANTED FOR FASLODEX™ (FULVESTRANT) IN EUROPEAN UNION AstraZeneca announced today that it has received European marketing approval for its new breast cancer drug FASLODEX™ (fulvestrant). ‘Faslodex’ is indicated for the treatment of advanced breast cancer in post-menopausal women whose cancer has progressed on previous anti-oestrogen treatments such as tamoxifen. This is the first new type of treatment for hormone receptor positive advanced breast cancer to be approved in the European Union since 1995.
-
- 11 March 2004
- ASTRAZENECA BOARD ANNOUNCEMENT AstraZeneca PLC today announces the appointment of Louis Schweitzer, presently Chairman and CEO of Renault, as a non-executive Director. It is planned that he will be appointed as non-executive Chairman later this year. Percy Barnevik will then retire from the Board as Chairman and a Director.
-
- 25 February 2004
- ASTRAZENECA ISSUES 2003 ANNUAL REPORT AstraZeneca today published its Annual Report and Form 20-F for 2003 and its 2003 Annual Review. These documents are available on the company’s website www.astrazeneca.com, (click on Investor Relations - Annual Reports ).
-
- 29 January 2004
- AstraZeneca PLC Fourth Quarter and Full Year Results 2003 “Achievements in 2003 position AstraZeneca for strong sales and profit growth”
-
- 29 January 2004
- ASTRAZENECA SUBMITS REGULATORY APPLICATIONS FOR NEXIUM® IN US AND EUROPE FOR HEALING AND PREVENTION OF NSAID-ASSOCIATED ULCERS AstraZeneca today announced the submission of regulatory applications to the United States Food and Drug Administration (FDA), the European Union (EU) and other global markets for two indications related to the Non-steroidal anti-inflammatory drugs (NSAID)-associated gastrointestinal (GI) side effect programme for NEXIUM®. These indications are for the use of NEXIUM® for the healing of NSAID-associated gastric ulcers and prevention of NSAID-associated gastric and duodenal ulcers in patients at risk, in
-
- 14 January 2004
- SUCCESSFUL OUTCOME OF EUROPEAN MUTUAL RECOGNITION PROCEDURE FOR ASTRAZENECA’S NEXIUM I.V. AstraZeneca today announced that the European Mutual Recognition Procedure (MRP) for the intravenous (i.v.) formulation of Nexium® has been successfully completed.
-
- 13 January 2004
- ASTRAZENECA RECEIVES FDA APPROVAL FOR SEROQUEL™ AstraZeneca today announced that the U.S. Food and Drug Administration (FDA) has approved SEROQUEL (quetiapine) as a monotherapy and adjunct therapy for the treatment of mania associated with bipolar disorder (manic-depressive illness).
Not signed in
Page tools
Share price
- London
-
26.95 GBP - New York
-
44.82 USD
- Stockholm
-
310.10 SEK
At 21-Nov-2009 10:43 GMT
Detailed share priceIntroduction to AstraZeneca
Our responsibility
We continue to communicate openly on a range of issues, including:
